BIG PHARMA WATCH: AARP REPORT FINDS BIG PHARMA HIKES PRICES ON TOP-SELLING BLOCKBUSTERS IN MEDICARE PART D BY AVERAGE OF 98 PERCENT
Brand Name Drug Companies Nearly Double Prices on Medications Most Often… Read More
© 2025 CSRXP- All Rights Reserved
DOSE OF REALITY: BIG PHARMA WELCOMES 2025 WITH PRICE HIKES
Brand Name Drug Companies Increase Prices By More Than Rate of Inflation in… Read More
CSRXP: BIG PHARMA BACK AT IT WITH EGREGIOUS PRICE HIKES OUTPACING INFLATION TO RING IN 2025
Brand Name Drug Companies Signal Business-as-Usual Approach to Price-Gouging… Read More
CSRxP: DISAPPOINTED CONGRESS DID NOT PASS CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS TO HOLD BIG PHARMA ACCOUNTABLE, INCREASE COMPETITION
Campaign Will Work with Lawmakers in the New Congress and the New… Read More
DOSE OF REALITY: CONGRESS CAN HOLD BIG PHARMA ACCOUNTABLE FOR GAMING THE SYSTEM TO BLOCK COMPETITION, KEEP DRUG PRICES HIGH
Lawmakers Should Pass Bipartisan, Market-Based Solutions to Crack Down on… Read More
CSRxP: PASSAGE OF CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS WOULD BE POSITIVE STEPS TOWARD HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE
Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent… Read More
ICYMI: CSRxP ANALYSIS FINDS PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS TEN TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN
Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More
ICYMI: AARP URGES PASSAGE OF PRESCRIPTION DRUG LEGISLATION BY YEAR’S END
AARP Urges Lawmakers to Pass Cornyn-Blumenthal On Friday, AARP urged lawmakers… Read More
BIG PHARMA WATCH: UNJUSTIFIED PRICE HIKES ON FIVE BRAND NAME DRUGS COST U.S. $815 MILLION IN 2023
ICER Analysis Highlights Big Pharma Price Hikes Outpacing Inflation on Brand… Read More
CSRxP: USPTO WITHDRAWAL OF PATENT THICKET RULE ADDS TO URGENCY FOR CONGRESS TO PASS CORNYN-BLUMENTHAL
Lawmakers Must Act to Hold Big Pharma Accountable for Egregious Patent Abuse… Read More
BIG PHARMA WATCH: MERCK TAKES ANOTHER STEP TOWARD FURTHER EXTENDING PATENT EXCLUSIVITY ON BLOCKBUSTER CANCER DRUG KEYTRUDA
Big Pharma Giant Proceeds With Strategy to Block Competition, Add More Patents… Read More
CSRxP STATEMENT ON SENATE JUDICIARY MARKUP OF THE PREVAIL ACT
Congress Should Not Further Consider Misguided Proposal That Would Enable More… Read More